NCT05827614 - Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications | Biotech Hunter

Enrollment

127

Participants

Timeline

Start Date

March 24, 2023

Primary Completion Date

September 30, 2026

Study Completion Date

March 31, 2027

Conditions

Triple Negative Breast Cancer (TNBC)High Grade Serous Ovarian CarcinomaHigh Grade Endometrial CarcinomaAnogenital CancerHead and Neck (HNSCC)Cutaneous Squamous Cell Carcinoma (CSCC)Cervical Squamous Cell CarcinomaER+ Breast CancerLeiomyosarcoma (LMS)Undifferentiated Pleomorphic Sarcoma (UPS)Pancreatic Cancer MetastaticSmall Cell Lung Cancer

Interventions

DRUG

BBI-355

Oral CHK1 inhibitor

DRUG

Erlotinib

EGFR Inhibitor

DRUG

Futibatinib

FGFR1-4 Inhibitor

DRUG

BBI-825

Oral RNR Inhibitor

Trial Locations (17)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

22031

RECRUITING

NEXT Oncology, Fairfax

29425

WITHDRAWN

Medical University of South Carolina, Charleston

32746

ACTIVE_NOT_RECRUITING

Florida Cancer Specialists, Lake Mary

37203

ACTIVE_NOT_RECRUITING

SCRI Oncology Partners, Nashville

49546

RECRUITING

START Midwest, Grand Rapids

53792

ACTIVE_NOT_RECRUITING

University of Wisconsin, Madison

66205

ACTIVE_NOT_RECRUITING

The University of Kansas, Fairway

75039

RECRUITING

NEXT Oncology - Dallas, Irving

77054

RECRUITING

MD Anderson Cancer Center, Houston

78229

RECRUITING

NEXT Oncology, San Antonio

80218

RECRUITING

HealthONE, Denver

90095

ACTIVE_NOT_RECRUITING

UCLA Medical Center, Los Angeles

90403

TERMINATED

Sarcoma Oncology, Santa Monica

98109

RECRUITING

University of Washington, Fred Hutchinson Cancer Center, Seattle

02215

RECRUITING

Beth Israel Deaconess Medical Center, Boston

RECRUITING

Dana Farber Cancer Institute, Boston